SILK-DERIVED PROTEIN TECHNOLOGY


Technology

Amlisimod is a Broad Spectrum
Anti-Inflammatory
Biologic Drug Candidate


SilkTech Biopharmaceuticals is a drug discovery and development company specializing in the isolation and cGMP manufacturing of patented silk-derived proteins (SDP) from the domesticated Bombyx mori silkworm cocoon.
Image
Amlisimod Inhibits Cytokine Production & Release
THE NF-kB INFLAMMATORY PATHWAY

Over-activation of the NF-kB pathway negatively impacts health by driving inflammatory signaling. Kinase proteins activate the NF-kB pathway, driving inflammatory gene expression. Over time, this may worsen a patient's symptoms and disease severity.

Image
 
Placeholder headline text is placed here

SilkTech Biopharmaceuticals is a drug discovery and development company specializing in the isolation and cGMP manufacturing of patented silk-derived proteins (SDP) from the domesticated Bombyx mori silkworm cocoon.
Image

Amlisimod Works to Combat Inflammation in a Novel Way

Amlisimod works to reduce over-activation of the NF-kB pathway by redirecting activating kinases. As a result, amlisimod is designed to balance inflammatory activity inside the cell without creating toxic side effects commonly scene with other therapeutic approaches.
Image
Image Image
Epithelial cell uptake in 1 hour to inhibit NF-kB pathway activation at 1mg/mL.
Image
Epithelial cell uptake in 1 hour to inhibit NF-kB pathway activation at 1mg/mL.
Image
DERIVED FROM NATURAL SILK
Produced from the Bombyx mori silkworm cocoon
Image Image
Amlisimod Protein
Non-Toxic and Non-Immunogenic; designed to reduce inflammation
Image Image

Broad Spectrum

Broader biological activity with less toxicity

How does Amlisimod reduce inflammation?

Image

Amlisimod works through a novel mechanism of action by reducing activation of NF-kB through redirecting the kinase proteins that activate it. This works to balance cellular inflammatory activity, and is designed to reduce symptom severity for the patient.

Amlisimod Inhibits Cytokine Production & Release

Amlisimod reduces immune cell migration & cytokine release

• Reduced human immune cell migration rate back to baseline
• Reduced epithelial IL-8 cytokine secretion dose dependently
Amlisimod Inhibits Cytokine Production & Release

Amlisimod reduces immune cell migration & cytokine release

• Reduced human immune cell migration rate back to baseline
• Reduced epithelial IL-8 cytokine secretion dose dependently
Amlisimod Reduces Presence of MMP-9
Placeholder headline text is placed here

SilkTech Biopharmaceuticals is a drug discovery and development company specializing in the isolation and cGMP manufacturing of patented silk-derived proteins (SDP) from the domesticated Bombyx mori silkworm cocoon.
Image
Amlisimod Enhanced Cell Regeneration in an Animal Model
Image